These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 36126241

  • 1. Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study.
    Papasouliotis O, Mitchell D, Girard P, Dangond F, Dyroff M.
    Clin Transl Sci; 2022 Dec; 15(12):2888-2898. PubMed ID: 36126241
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants.
    Papasouliotis O, Mitchell D, Girard P, Dyroff M.
    Clin Transl Sci; 2022 Dec; 15(12):2899-2908. PubMed ID: 36165192
    [Abstract] [Full Text] [Related]

  • 3. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
    Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS, Evobrutinib Phase 2 Study Group.
    N Engl J Med; 2019 Jun 20; 380(25):2406-2417. PubMed ID: 31075187
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
    Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS.
    Mult Scler; 2024 Apr 20; 30(4-5):558-570. PubMed ID: 38436271
    [Abstract] [Full Text] [Related]

  • 5. A Phase 1 First-in-Human Pharmacokinetic and Pharmacodynamic Study of JNJ-64264681, a Covalent Inhibitor of Bruton's Tyrosine Kinase.
    Leu JH, Miao X, Shalayda K, Coe KJ, Kahnt A, Wu B, Schnarr M, Franks C, Devlin J, Yang TY, Palmer JA, Zhang M, Zhou H, Van Damme W, Smets S, Aguilar Z, Chaplan SR.
    Clin Pharmacol Drug Dev; 2023 Jun 20; 12(6):611-624. PubMed ID: 37125450
    [Abstract] [Full Text] [Related]

  • 6. Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Arnold DL, Elliott C, Martin EC, Hyvert Y, Tomic D, Montalban X.
    Neurology; 2024 Mar 12; 102(5):e208058. PubMed ID: 38335474
    [Abstract] [Full Text] [Related]

  • 7. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
    Becker A, Martin EC, Mitchell DY, Grenningloh R, Bender AT, Laurent J, Mackenzie H, Johne A.
    Clin Transl Sci; 2020 Mar 12; 13(2):325-336. PubMed ID: 31654487
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
    Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D, evolutionRMS investigators.
    Lancet Neurol; 2024 Nov 12; 23(11):1119-1132. PubMed ID: 39307151
    [Abstract] [Full Text] [Related]

  • 9. Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
    Montalban X, Wallace D, Genovese MC, Tomic D, Parsons-Rich D, Le Bolay C, Kao AH, Guehring H.
    J Neurol Neurosurg Psychiatry; 2023 Jan 12; 94(1):1-9. PubMed ID: 36418156
    [Abstract] [Full Text] [Related]

  • 10. Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor.
    Bar-Or A, Cross AH, Cunningham AL, Hyvert Y, Seitzinger A, Gühring H, Drouin EE, Alexandri N, Tomic D, Montalban X.
    Mult Scler; 2023 Oct 12; 29(11-12):1471-1481. PubMed ID: 37626477
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial.
    Wallace DJ, Dörner T, Pisetsky DS, Sanchez-Guerrero J, Patel AC, Parsons-Rich D, Le Bolay C, Drouin EE, Kao AH, Guehring H, Dall'Era M.
    ACR Open Rheumatol; 2023 Jan 12; 5(1):38-48. PubMed ID: 36530019
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
    Haselmayer P, Camps M, Liu-Bujalski L, Nguyen N, Morandi F, Head J, O'Mahony A, Zimmerli SC, Bruns L, Bender AT, Schroeder P, Grenningloh R.
    J Immunol; 2019 May 15; 202(10):2888-2906. PubMed ID: 30988116
    [Abstract] [Full Text] [Related]

  • 13. Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants.
    Scheible H, Dyroff M, Seithel-Keuth A, Harrison-Moench E, Mammasse N, Port A, Bachmann A, Dong J, van Lier JJ, Tracewell W, Mitchell D.
    Clin Transl Sci; 2021 Nov 15; 14(6):2420-2430. PubMed ID: 34374206
    [Abstract] [Full Text] [Related]

  • 14. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
    Caldwell RD, Qiu H, Askew BC, Bender AT, Brugger N, Camps M, Dhanabal M, Dutt V, Eichhorn T, Gardberg AS, Goutopoulos A, Grenningloh R, Head J, Healey B, Hodous BL, Huck BR, Johnson TL, Jones C, Jones RC, Mochalkin I, Morandi F, Nguyen N, Meyring M, Potnick JR, Santos DC, Schmidt R, Sherer B, Shutes A, Urbahns K, Follis AV, Wegener AA, Zimmerli SC, Liu-Bujalski L.
    J Med Chem; 2019 Sep 12; 62(17):7643-7655. PubMed ID: 31368705
    [Abstract] [Full Text] [Related]

  • 15. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
    Steinmaurer A, Wimmer I, Berger T, Rommer PS, Sellner J.
    Curr Pharm Des; 2022 Sep 12; 28(6):437-444. PubMed ID: 34218776
    [Abstract] [Full Text] [Related]

  • 16. Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective.
    Scheible H, Schieferstein H, Schmidt R, Pusecker K, Gradhand U, Gopalakrishnan S, Iqbal K, Dong J, Jones R, Meli C, Bolleddula J, Dyroff M, Georgi K.
    Xenobiotica; 2023 Dec 12; 53(8-9):547-558. PubMed ID: 37880944
    [Abstract] [Full Text] [Related]

  • 17. A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis.
    Montalban X, Wallace D, Genovese MC, Tomic D, Parsons-Rich D, Bolay CL, Kao AH, Guehring H.
    Neurodegener Dis Manag; 2023 Aug 12; 13(4):207-213. PubMed ID: 37345645
    [Abstract] [Full Text] [Related]

  • 18. Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib.
    Rijvers L, van Langelaar J, Bogers L, Melief MJ, Koetzier SC, Blok KM, Wierenga-Wolf AF, de Vries HE, Rip J, Corneth OB, Hendriks RW, Grenningloh R, Boschert U, Smolders J, van Luijn MM.
    JCI Insight; 2022 Aug 22; 7(16):. PubMed ID: 35852869
    [Abstract] [Full Text] [Related]

  • 19. Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.
    Herman AE, Chinn LW, Kotwal SG, Murray ER, Zhao R, Florero M, Lin A, Moein A, Wang R, Bremer M, Kokubu S, Serone AP, Hanze EL, Viberg A, Morimoto AM, Winter HR, Katsumoto TR.
    Clin Pharmacol Ther; 2018 Jun 22; 103(6):1020-1028. PubMed ID: 29484638
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, Skripchenko N, Cui LY, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M, TERIKIDS Investigators.
    Lancet Neurol; 2021 Dec 22; 20(12):1001-1011. PubMed ID: 34800398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.